Tristetraprolin (TTP) Plasmid Vectors for Human and Mouse TTP


Tristetraprolin (TTP) is involved in the physiological regulation of the secretion of at least two important cytokines, tumor necrosis factor alpha (TNF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). TTP exerts its effects by directly binding to the mRNAs encoding these proteins and destabilizing them, resulting in less secretion. Conversely, TTP deficiency results in an excess of both cytokines, leading to a systemic inflammatory syndrome. This invention include three categories of reagents related to TTP:1) Plasmid DNAs and mammalian expression vectors for human and mouse TTP; 2) Antibodies (rabbit antisera) to human and mouse TTP; 3) Immortalized macrophage cell lines derived from TTP-deficient mice and their wild-type littermates.

Potential Commercial Applications: Competitive Advantages:
  • Reagents and cell lines relating to TTP are useful in the study of inflammation from various perspectives, particularly in the study of the new pathway delineated by these studies for the regulation of these cytokines and their secretion.
 


Inventors:

Perry Blackshear (NIEHS)  ➽ more inventions...

Wi Lai (NIEHS)  ➽ more inventions...


Intellectual Property:
Research Tool – Patent protection is not being pursued for this technology.

Licensing Contact:
Vidita Choudhry, Ph.D.
Email: vidita.choudhry@nih.gov
Phone: 301-594-4095

OTT Reference No: E-349-2001-0
Updated: Dec 2, 2016